Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Update

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 61,400 shares, an increase of 2,174.1% from the December 15th total of 2,700 shares. Based on an average daily trading volume, of 26,100 shares, the days-to-cover ratio is currently 2.4 days. Approximately 0.7% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Separately, Benchmark reaffirmed a “speculative buy” rating and set a $8.00 price target on shares of Anebulo Pharmaceuticals in a research report on Tuesday, November 19th.

Insiders Place Their Bets

In other Anebulo Pharmaceuticals news, Director Aron R. English acquired 10,101,010 shares of Anebulo Pharmaceuticals stock in a transaction that occurred on Monday, December 23rd. The shares were bought at an average price of $0.99 per share, with a total value of $9,999,999.90. Following the completion of the purchase, the director now directly owns 15,467,300 shares in the company, valued at $15,312,627. This trade represents a 188.23 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 85.90% of the company’s stock.

Anebulo Pharmaceuticals Stock Up 4.0 %

ANEB traded up $0.06 during trading on Wednesday, reaching $1.66. 911 shares of the stock traded hands, compared to its average volume of 18,735. The stock has a market capitalization of $43.05 million, a PE ratio of -5.53 and a beta of -1.14. The stock’s 50-day moving average is $1.51 and its 200 day moving average is $1.86. Anebulo Pharmaceuticals has a 12 month low of $0.80 and a 12 month high of $3.30.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.